CVM · CEL-SCI Corporation

CEL-SCI Corporation operates at the high-risk, high-stakes intersection of late-stage clinical development and capital-constrained biotech. Its entire value proposition rests on Multikine, an investigational immunotherapy that showed a statistically significant 73% five-year survival rate versus 45% in the control arm of its Phase III trial — but only in a narrowly defined target population: newly diagnosed, locally advanced, PD-L1-low, lymph-node-negative head and neck cancer patients. This precision focus creates both opportunity and vulnerability: while it positions Multikine to address a clear unmet medical need where existing immunotherapies fail, it also means regulatory success hinges on validating this specific biomarker-defined cohort in a smaller, confirmatory 212-patient study — a step requiring both scientific execution and sufficient capital. The company’s business model remains pre-revenue, with no approved products and no dividends planned; its sole near-term path to value creation is regulatory approval, followed by commercialization. Financially, CEL-SCI is burning cash rapidly — reporting a $5.47 million net loss for just the three months ending December 31, 2025, with only $6.28 million in cash against $22.9 million in total assets. This precarious liquidity underscores why the $13.7 million in estimated net proceeds from this S-1 is mission-critical: it is explicitly earmarked for Multikine’s continued development and general corporate purposes, with management retaining broad discretion over allocation — a red flag for investors seeking accountability. The offering mechanics further reflect structural constraints: it is a best-efforts placement with no minimum raise, meaning CEL-SCI could fall far short of its funding goal, and the inclusion of Pre-Funded Warrants — priced to bypass 4.99% ownership thresholds — signals reliance on investors who face regulatory or internal investment restrictions, while simultaneously limiting their rights and upside until exercise. Compounding these challenges are serious governance and operational risks: the company has disclosed material weaknesses in its internal financial controls, faces a mandatory ‘bridging study’ to align its PD-L1 assay with an FDA-approved companion diagnostic, and carries a going-concern qualification from its auditors. These are not generic biotech risks — they are specific, near-term hurdles that could derail the entire development timeline. For investors, this offering is less about growth potential and more about existential viability: it represents the capital required to cross the final regulatory threshold, with failure implying continued losses, dilution, and heightened risk of insolvency. The absence of revenue, profitability, or even a clear commercialization partner makes valuation purely speculative and contingent on binary regulatory outcomes.